BioQuadrant Pharmaceutical Intermediates Inc.

EV-077 - BioQuadrant performed scale-up of this experimental drug substance (2006). https://www.evolva.com//evolva-concludes-licensing-of-ev-/

R-954, a Bradykinin B1 antagonist we worked on at BioQuadrant (cGMP synthesis; 50 grams). http://www.ncbi.nlm.nih.gov/pubmed/24361511

One of the projects we supported made it into clinical trials. TMB-607 (formerly coded PPL-100 by Ambrilia and MK-8122 by Merck) is a novel HIV-1 protease inhibitor. It was initially developed by Ambrilia Biopharma Inc (Procyon). PL-100 was originally developed by Pharmacor (Laval, Canada) http://www.taimedbiologics.com/pipeline/35

Elamipretide. Discovered by Dr. Peter Schiller at the Clinical Research Institute of Montreal. One of the products we worked on at BioQuadrant. https://www.prnewswire.com//stealth-biotherapeutics-grante

BA-1049; One of the products BioQuadrant worked on. http://bioaxonebio.com/technology-overview/pipeline/

BioQuadrant client Locemia Solutions acquired by Eli-Lilly & Co. A success story! This new intranasal formulation for Glucagon was created at BioQuadrant's research labs. http://www.locemia.com//lilly-acquires-phase-iii-intranasa

Screenshots of our former web site

Biotechnology Focus features an article on the CQIB, the incubator where BioQuadrant started its operations. The article contains a photo taken in one of BioQuadrant's research labs. http://biotechnologyfocus.ca/?p=1702

BioQuadrant advertisements (web & print) showcasing our products and services.